tiprankstipranks
Intellia Therapeutics announces FDA clearance of IND for NTLA-2002
The Fly

Intellia Therapeutics announces FDA clearance of IND for NTLA-2002

ntellia Therapeutics announced that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application for NTLA-2002 for the treatment of hereditary angioedema, enabling the company to include the United States in the global Phase 2 portion of its ongoing Phase 1/2 study. NTLA-2002 is an in vivo genome editing candidate designed to inactivate the target gene, kallikrein B1, to permanently reduce plasma kallikrein protein activity and thus prevent HAE attacks after a single-dose treatment.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on NTLA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles